Polymyositis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major polymyositis markets are expected to exhibit a CAGR of 3.52% during 2024-2034.
The polymyositis market has been comprehensively analyzed in IMARC's new report titled "Polymyositis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Polymyositis is a rare autoimmune disease characterized by chronic inflammation and progressive weakening of the skeletal muscles. This condition primarily affects the muscles closest to the trunk of the body, such as those in the hips, thighs, shoulders, and neck. The symptoms of the ailment typically include muscle weakness, muscle pain, and fatigue. Individuals suffering from this illness may also experience difficulty climbing stairs, lifting objects, or even getting up from a seated position. As the condition advances, it can result in muscle atrophy and impair one's ability to perform everyday tasks. The diagnosis of polymyositis involves a combination of clinical evaluation, blood tests, electromyography (EMG), and a muscle biopsy. Elevated concentrations of muscle enzymes, such as creatine kinase (CK), in the blood often indicate muscle damage. Furthermore, EMG helps to assess muscle function, while a muscle biopsy provides definitive evidence of inflammation and muscle fiber damage.
The escalating cases of rare autoimmune diseases, which mainly affect the skeletal muscles and cause abnormalities in the production of autoantibodies, are primarily driving the polymyositis market. In addition to this, the inflating utilization of potent medications, such as corticosteroids, immunosuppressants, and intravenous immunoglobulins, to manage the symptoms and mitigate the immune system's response against the muscles is also creating a positive outlook for the market. These therapies play a crucial role in reducing inflammation and enhancing muscle function, thereby improving the quality of life for individuals suffering from the ailment. Moreover, the widespread adoption of physical and occupational therapies on account of their several benefits, like restoring muscle strength, stabilizing mobility, and boosting overall physical activity, is further bolstering the market growth. Apart from this, the rising usage of novel therapeutic approaches, such as biologics and targeted therapies, which can address the underlying immune system dysfunction and decrease the frequency of disease relapses, thereby offering more effective and targeted solutions for patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapies aimed at rectifying genetic anomalies and regulating aberrant immune responses responsible for the disorder is expected to drive the polymyositis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the polymyositis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for polymyositis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polymyositis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the polymyositis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the polymyositis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current polymyositis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the polymyositis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the polymyositis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the polymyositis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of polymyositis across the seven major markets?
What is the number of prevalent cases (2018-2034) of polymyositis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of polymyositis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with polymyositis across the seven major markets?
What is the size of the polymyositis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of polymyositis?
What will be the growth rate of patients across the seven major markets?
Polymyositis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for polymyositis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the polymyositis market?
What are the key regulatory events related to the polymyositis market?
What is the structure of clinical trial landscape by status related to the polymyositis market?
What is the structure of clinical trial landscape by phase related to the polymyositis market?
What is the structure of clinical trial landscape by route of administration related to the polymyositis market?
The polymyositis market has been comprehensively analyzed in IMARC's new report titled "Polymyositis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Polymyositis is a rare autoimmune disease characterized by chronic inflammation and progressive weakening of the skeletal muscles. This condition primarily affects the muscles closest to the trunk of the body, such as those in the hips, thighs, shoulders, and neck. The symptoms of the ailment typically include muscle weakness, muscle pain, and fatigue. Individuals suffering from this illness may also experience difficulty climbing stairs, lifting objects, or even getting up from a seated position. As the condition advances, it can result in muscle atrophy and impair one's ability to perform everyday tasks. The diagnosis of polymyositis involves a combination of clinical evaluation, blood tests, electromyography (EMG), and a muscle biopsy. Elevated concentrations of muscle enzymes, such as creatine kinase (CK), in the blood often indicate muscle damage. Furthermore, EMG helps to assess muscle function, while a muscle biopsy provides definitive evidence of inflammation and muscle fiber damage.
The escalating cases of rare autoimmune diseases, which mainly affect the skeletal muscles and cause abnormalities in the production of autoantibodies, are primarily driving the polymyositis market. In addition to this, the inflating utilization of potent medications, such as corticosteroids, immunosuppressants, and intravenous immunoglobulins, to manage the symptoms and mitigate the immune system's response against the muscles is also creating a positive outlook for the market. These therapies play a crucial role in reducing inflammation and enhancing muscle function, thereby improving the quality of life for individuals suffering from the ailment. Moreover, the widespread adoption of physical and occupational therapies on account of their several benefits, like restoring muscle strength, stabilizing mobility, and boosting overall physical activity, is further bolstering the market growth. Apart from this, the rising usage of novel therapeutic approaches, such as biologics and targeted therapies, which can address the underlying immune system dysfunction and decrease the frequency of disease relapses, thereby offering more effective and targeted solutions for patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapies aimed at rectifying genetic anomalies and regulating aberrant immune responses responsible for the disorder is expected to drive the polymyositis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the polymyositis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for polymyositis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polymyositis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the polymyositis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the polymyositis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current polymyositis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the polymyositis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the polymyositis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the polymyositis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of polymyositis across the seven major markets?
What is the number of prevalent cases (2018-2034) of polymyositis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of polymyositis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with polymyositis across the seven major markets?
What is the size of the polymyositis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of polymyositis?
What will be the growth rate of patients across the seven major markets?
Polymyositis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for polymyositis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the polymyositis market?
What are the key regulatory events related to the polymyositis market?
What is the structure of clinical trial landscape by status related to the polymyositis market?
What is the structure of clinical trial landscape by phase related to the polymyositis market?
What is the structure of clinical trial landscape by route of administration related to the polymyositis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POLYMYOSITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POLYMYOSITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POLYMYOSITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 POLYMYOSITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POLYMYOSITIS - UNMET NEEDS
10 POLYMYOSITIS - KEY ENDPOINTS OF TREATMENT
11 POLYMYOSITIS - MARKETED PRODUCTS
11.1 List of Polymyositis Marketed Drugs Across the Top 7 Markets
11.1.1 Acthar (Corticotropin) - Mallinckrodt
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 POLYMYOSITIS - PIPELINE DRUGS
12.1 List of Polymyositis Pipeline Drugs Across the Top 7 Markets
12.1.1 M5049 - Merck
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POLYMYOSITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POLYMYOSITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POLYMYOSITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Polymyositis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Polymyositis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Polymyositis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Polymyositis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Polymyositis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Polymyositis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Polymyositis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Polymyositis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Polymyositis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Polymyositis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Polymyositis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Polymyositis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Polymyositis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Polymyositis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Polymyositis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Polymyositis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Polymyositis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Polymyositis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Polymyositis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Polymyositis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Polymyositis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Polymyositis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Polymyositis - Access and Reimbursement Overview
16 POLYMYOSITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POLYMYOSITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POLYMYOSITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POLYMYOSITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POLYMYOSITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POLYMYOSITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 POLYMYOSITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POLYMYOSITIS - UNMET NEEDS
10 POLYMYOSITIS - KEY ENDPOINTS OF TREATMENT
11 POLYMYOSITIS - MARKETED PRODUCTS
11.1 List of Polymyositis Marketed Drugs Across the Top 7 Markets
11.1.1 Acthar (Corticotropin) - Mallinckrodt
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 POLYMYOSITIS - PIPELINE DRUGS
12.1 List of Polymyositis Pipeline Drugs Across the Top 7 Markets
12.1.1 M5049 - Merck
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. POLYMYOSITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POLYMYOSITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POLYMYOSITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Polymyositis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Polymyositis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Polymyositis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Polymyositis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Polymyositis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Polymyositis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Polymyositis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Polymyositis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Polymyositis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Polymyositis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Polymyositis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Polymyositis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Polymyositis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Polymyositis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Polymyositis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Polymyositis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Polymyositis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Polymyositis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Polymyositis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Polymyositis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Polymyositis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Polymyositis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Polymyositis - Access and Reimbursement Overview
16 POLYMYOSITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POLYMYOSITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POLYMYOSITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
